NCT05727657View on ClinicalTrials.gov

Satralizumab in Aneurysmal Subarachnoid Hemorrhage

EARLY_PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2024

Conditions

Aneurysmal Subarachnoid HemorrhageDelayed Cerebral Ischemia

Interventions

DRUG

Satralizumab

120mg subcutaneous Day 0 and Day 14

Trial Locations (1)

32608

University of Florida (UF) Health Shands Hospital, Gainesville

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Florida

OTHER

NCT05727657 - Satralizumab in Aneurysmal Subarachnoid Hemorrhage | Biotech Hunter | Biotech Hunter